Finance entity
Every one of those 2 sits in a single category, earnings. Lantheus Holdings is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Their average consequence score of 5 runs below the beat's 5.9 for that window.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 2 sits in a single category, earnings. Lantheus Holdings is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Their average consequence score of 5 runs below the beat's 5.9 for that window. Each story carries 3 original sources on average, compared with 2.7 for the broader beat in this window. Heron Therapeutics appears in 2 tracked Finance stories published from February 25, 2026 through February 26, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 216 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Heron Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
Lantheus Holdings and Heron Therapeutics both reported mixed fourth-quarter results for 2025, characterized by revenue growth offset by margin pressures. Crucially, both firms took the rare step of introducing fiscal year 2026 guidance, signaling a strategic shift toward long-term stability in the radiopharmaceutical and acute care markets.
As the Q4 2025 earnings season intensifies, four key players in the specialized medical technology and biotechnology sectors—Delcath Systems, Butterfly Network, Heron Therapeutics, and Lantheus Holdings—are preparing to report results. Investors are focusing on commercial execution, product adoption rates, and the sustainability of high-growth specialized therapies.
Heron Therapeutics is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
